



SESSION 4

Optimizing Management in IBD: Acute Severe Ulcerative Colitis

MEDICAL THERAPY OF ACUTE SEVERE ULCERATIVE COLITIS

Neeraj Narula, MD MPH FRCPC

This session will focus on management of acute severe ulcerative colitis in 2018, including: discussion on infliximab dosing in the hospitalized patient; the role of other biologic and non-biologic options in severe ulcerative colitis; and whether cyclosporine should still be considered and when..

References

Hindryckx P, Novak G, Vande Casteele N, et al. Review article: Dose optimization of infliximab for acute severe ulcerative colitis. *Aliment Pharmacol Ther.* 2017;45(5):617–30.

Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids. *Am J Gastroenterol.* 2016;111(4):477–91.

Narula N, Fine M, Colombel JF, et al. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks? *Inflamm Bowel Dis.* 2015;21(7):1683–94.